Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
IL19 Biologics Sequence Review Report 2026: Interleukin-19 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IL19 Biologics Sequence Review Report 2026: Interleukin-19 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of IL19 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IL17D Biologics Sequence Review Report 2026: Interleukin-17D Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IL17D Biologics Sequence Review Report 2026: Interleukin-17D Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of IL17D protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IL17C Biologics Sequence Review Report 2026: Interleukin-17C Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IL17C Biologics Sequence Review Report 2026: Interleukin-17C Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of IL17C protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IL17B Biologics Sequence Review Report 2026: Interleukin-17B Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IL17B Biologics Sequence Review Report 2026: Interleukin-17B Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of IL17B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IFNLR1 Biologics Sequence Review Report 2026: Interferon lambda receptor 1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IFNLR1 Biologics Sequence Review Report 2026: Interferon lambda receptor 1 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of IFNLR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IFNGR2 Biologics Sequence Review Report 2026: Interferon gamma receptor 2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IFNGR2 Biologics Sequence Review Report 2026: Interferon gamma receptor 2 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of IFNGR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IFNGR1 Biologics Sequence Review Report 2026: Interferon gamma receptor 1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IFNGR1 Biologics Sequence Review Report 2026: Interferon gamma receptor 1 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of IFNGR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IFNAR2 Biologics Sequence Review Report 2026: Interferon alpha/beta receptor 2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IFNAR2 Biologics Sequence Review Report 2026: Interferon alpha/beta receptor 2 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of IFNAR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IFNAR1 Biologics Sequence Review Report 2026: Interferon alpha/beta receptor 1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IFNAR1 Biologics Sequence Review Report 2026: Interferon alpha/beta receptor 1 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of IFNAR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ICAM4 Biologics Sequence Review Report 2026: Intercellular adhesion molecule 4 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ICAM4 Biologics Sequence Review Report 2026: Intercellular adhesion molecule 4 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of ICAM4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ICAM3 Biologics Sequence Review Report 2026: Intercellular adhesion molecule 3 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ICAM3 Biologics Sequence Review Report 2026: Intercellular adhesion molecule 3 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of ICAM3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ICAM2 Biologics Sequence Review Report 2026: Intercellular adhesion molecule 2 Similarity and Patent-Risk Signals
8 min read
ICAM2 Biologics Sequence Review Report 2026: Intercellular adhesion molecule 2 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of ICAM2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →